Derivatisation of biological molecules

ABSTRACT

The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula 
                         
The polymers are particularly suitable for derivatising proteins, such as interferon-α.

CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of pending U.S. application Ser. No.12/527,233, filed Aug. 14, 2009 (now allowed), which is a National Stageof International Application No. PCT/EP08/51675 filed Feb. 12, 2008,claiming priority based on European Patent Application No. 07102418.6,filed Feb. 14, 2007, the contents of all of which are incorporatedherein by reference in their entirety.

BACKGROUND OF THE INVENTION

The present invention relates to the modification of biologicalmolecules for the purpose of improving their efficacy as therapeutictreatments.

Traditionally, therapeutic proteins have several inherent shortcomings.Proteins often have short half-lives, wide tissue distribution, thepotential for immunogenicity, and sometimes need to be dosed frequently.When frequent dosing is required, it can result in increased cost,toxicity and complicated dosing regimens. In an effort to overcome theseshortcomings, researchers have looked at improving the delivery systemsof proteins. Among the potential solutions lies PEGylation, theattachment of a flexible strand or strands of polyethylene glycol (PEG)to a protein.

When attached to a drug or protein, PEG polymer chains can sustainbioavailability by protecting the drug molecules from immune responsesand other clearance mechanisms. PEGylation has been shown to favourablyalter pharmacokinetics by prolonging circulation time and decreasingclearance rates, to delay absorption, decrease systemic toxicity and todisplay increased clinical efficacy (partly by exhibiting reducedproteolysis).

Clinical developments are reported for PEG conjugates of proteins,peptides, aptamers, natural products and small molecules. For instance,PEG-asparaginase has been used in Oncaspar™ by Enzon to treat acutelymphoblastic leukemia and PEG-α-interferon 2b has been used by ScheringPlough to treat Hepatitis C.

WO 2005/007197 describes a series of novel reagents which can be used,inter alia, to conjugate thiol groups of two cysteine residues in aprotein to give novel thioether conjugates. The reagents comprisepolymers which may be, for example, a polyalkylene glycol, apolyacrylate or a HPMA polymer. It is disclosed that interferons may beconjugated, and their biological activity retained compared withnon-conjugated interferons.

Overall, PEG attachment to interferon-alpha leads to a longer half-lifeof the interferon. This occurs due to decreased clearance by the kidneyand reduced proteolysis (slower breakdown of protein). In addition, PEGattachment leads to lowered antigenicity of interferon. PEG attachmentalso leads to increased chemical and thermal (heat) stability of thebase substance interferon.

PEGylation, however, has its disadvantages. PEGylation of proteins isknown for its suboptimal yields; losses of 20-40% of protein andPEG-agent are not uncommon. Many of the common linking technologies arenon-specific and the protein can be PEGylated at multiple sites in arandom fashion, producing a mixture of products with variableactivities. It is important, for optimised efficacy to ensure that thenumber of conjugated polymer molecules per protein is the same and thateach polymer is attached to the same residue in each protein molecule.

Some have tried to avoid such problems by attaching PEG to theN-terminal amino group of proteins and peptides. This is calledN-terminal PEGylation. N-terminal PEGylation may offer advantages inpurification of the conjugates. It is also believed that the N-terminalPEGylation may better preserve bioactivity as compared to a randomPEGylation of amino group of lysine residues.

Thiol specific polymer conjugating reagents for proteins have beendeveloped. These are generally more hydrolytically stable than theiramino-specific counterparts and thus can be used at lower stoichiometricexcess. Conjugating functional moieties that are broadly selective forthiol groups include iodoacetamide, maleiimide (WO 92/16221),vinylsulfone (WO 95/13312 and WO 95/34326), vinyl pyridines (WO88/05433), and acrylate and methacrylate esters (WO 99/01469). Thesethiol selective conjugating moieties yield a single thioetherconjugating bond between the polymer.

Conjugation to a protein via a thiol residue is also advantageous sinceproteins typically contain few thiol groups, hence conjugation can bespecifically directed to a certain residue or residues on each protein.

SUMMARY OF THE INVENTION

This invention aims to address the issues with polymer-modification oftherapeutic agents and provides a novel method for the attachment of anew class of polymers for biological molecule modification.

Herein we describe polymers of controlled architecture made using suchmethods known in the art as atom transfer radical polymerisation (ATRP)or radical addition-fragmentation chain transfer polymerisation (RAFT)(U.S. Pat. No. 6,852,816). Such methods have been described in WO02/28929 for producing zwitterionic polymers having controlledarchitectures, specifically having controlled chain length and/orblocked chain length in block polymers. Although these methods are wellknown, they have not previously been used for the preparation ofcompounds to conjugate biological molecules according to this invention.

We have previously described methods of attaching phospholipid-basedpolymers to proteins via conventional linking technologies described inthe art (WO 2004/063237) or by modification of the protein into aninitiator for polymerisation of said polymers (WO 03/062290). Thepresent invention provides selective means for attaching polymers tobiological molecules, combining the advantageous properties of polymersproduced via living radical polymerisation with a reagent which isselective for particular groups on biological molecules, typically thiolgroups.

The controlled molecular weight, composition and architectures of thevarious polymers brings about a high degree of control in the propertiesof the polymers.

In accordance with a first aspect of the present invention we provide apolymerisation process in which ethylenically unsaturated monomers arepolymerised by a living radical polymerisation process in the presenceof an initiator of the general formula I or II and a catalyst

wherein R¹ is an electron-withdrawing group;

R² is selected from C═O, C(═O)NR⁹ or a bond; wherein R⁹ is H or C₁₋₄alkyl;

R³ is selected from the group consisting of C₁-C₂₀ alkylene, C₃-C₈cycloalkylene, C(═O)R¹⁰, C(═O)NR¹¹, C₁-C₂₀ alkoxy, C₂-C₂₀ alkenylene,C₂-C₂₀ alkenyl oxiranylene, arylene, heterocyclene and aralkylene; inwhich 0 to all of the hydrogen atoms are replaced with halogen, C₁-C₆alkyl optionally substituted with 1 to 2 substituents selected from thegroup consisting of C₁-C₄ alkoxy, aryl, heterocyclyl, C(═O)R¹³,C(═O)NR¹¹R¹², oxiranyl and glycidyl;

R¹⁰ is alkylene of from 1 to 20 carbon atoms, alkoxy from 1 to 20 carbonatoms, oligo(alkoxy) in which each alkoxy group has from 1 to 3 carbonatoms, aryloxy or heterocyclyloxy; any of which groups may havesubstituents selected from optionally substituted alkoxy, oligoalkoxy,amino (including mono- and di-alkyl amino and trialkyl ammonium, whichalkyl groups, in turn, may have substituents selected from acyl,alkoxycarbonyl, alkenoxycarbonyl, aryl and hydroxy) and hydroxyl groups;

R¹¹ and R¹² are independently H or alkyl of from 1 to 20 carbon atoms,or R¹¹ and R¹² may be joined together to form an alkanediyl group offrom 2 to 5 carbon atoms, thus forming a 3- to 6-membered ring;

R⁴ and R⁵ are each independently selected from H, Z, halogen, C₁₋₂₀alkyl, C₃-C₈ cycloalkyl, OH, CN, C₂-C₂₀ alkenyl, C₂-C₂₀ alkenyloxiranyl, C(═O)R¹³, glycidyl, aryl, heterocyclyl, arylkyl, aralkenyl, inwhich 0 to all of the hydrogen atoms are replaced with halogen, C₁-C₆alkyl optionally substituted with 1 to 2 substituents selected from thegroup consisting of C₁-C₄ alkoxy, aryl, heterocyclyl, C(═O)R¹³,C(═O)NR¹¹R¹², oxiranyl and glycidyl;

where R¹³ is alkyl of from 1 to 20 carbon atoms, alkoxy of from 1 to 20carbon atoms, oligo(alkoxy) in which each alkoxy group has 1 to 3 carbonatoms, aryloxy or heterocyclyloxy any of which groups may havesubstituents selected from optionally substituted alkoxy, oligoalkoxy,amino (including mono- and di-alkyl amino and trialkyl ammonium, whichalkyl groups, in turn may have substituents selected from acyl,alkoxycarbonyl, alkenoxycarbonyl, aryl and hydroxy) and hydroxyl groups;and

L is a linking group;

Z is selected from the group consisting of Cl, Br, I, OR¹⁴, SR¹⁵, SeR¹⁵,OP(═O)R¹⁵, OP(═O)(═OR¹⁵)₂, O—N(R¹⁵)₂ and S—C(═S)N(R¹⁵)₂, where R¹⁴ isalkyl of from 1 to 20 carbon atoms in which each of the hydrogen atomsmay be independently replaced by halide, R¹⁵ is aryl or a straight orbranched C₁-C₂₀ alkyl group, and where an N(R¹⁵)₂ group is present, thetwo R¹⁵ groups may be joined to form a 5- or 6-membered heterocyclicring;

R⁶ is CH₂E², H or C₁₋₄ alkyl;

R⁷ and R⁸ are each independently selected from H and C₁₋₄ alkyl;

m is 0-4; and

E¹ and E² are each, independently, a leaving group, or a precursor to aleaving group.

Compounds of general formula I or II are also novel. Accordingly, asecond aspect of this invention provides compounds of general formula Ior II

wherein R¹-R⁶, R⁷-R⁸ (if present), L, Z, m and E¹ are as defined abovein the first aspect of this invention.

According to a third aspect of the present invention, we provide apolymer of general formula VII or VIII

wherein R¹-R⁶, R⁷-R⁸ (if present), L, Z, m and E¹ are as defined in thefirst aspect of the invention

f is 1 to 500; and

Groups M are the same or different and are residues of ethylenicallyunsaturated monomers.

These novel polymers are preferably produced in a process according tothe first aspect of this invention.

The novel polymers may be used to derivatise biological molecules.Accordingly, the fourth aspect of this invention provides a method ofderivatisation of a biological molecule in which a polymer of generalformula X or general formula XI

is added to a biological molecule of general formula T¹D¹X or tobiological molecules of general formula T¹D¹X and T²D²X, wherein D is S,NH or O and X is H, D¹T¹ or D²T² to form an adduct of general formulaXII or of general formula XIII

wherein R¹-R⁵, R⁷-R⁸ (if present), m and L are as defined in the firstaspect of the invention and M is as defined above in the third aspect ofthe invention;

f is 1 to 500;

R³⁶ is —CH₂E⁴, H or C₁₋₄ alkyl; and

E³ and E⁴ are each, independently, a leaving group,

x is 1 or 2;

p is 1-5 and q is 1-10.

We provide in a fifth aspect of this invention novel compounds ofgeneral formula XII or XIII as defined above.

The sixth aspect of this invention provides a pharmaceutical compositioncomprising a novel compound of general formula XII or XIII and apharmaceutically acceptable carrier.

A final aspect of this invention is the novel compound of generalformula XII or XIII, for use in therapy.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be illustrated by the following Examples, whichrefer to FIGS. 1-14, in which

FIG. 1 shows the mechanism of PC-polymer insertion into a proteindisulfide bridge;

FIG. 2 shows the ¹H NMR spectrum of initiator (4);

FIGS. 3 a and 3 b show the ¹H NMR spectra of MPC polymer withbis-sulfide (5(1)) and bis-sulfone (6(1)) end groups respectively;

FIG. 4 shows the SEC trace of PCylated IFN after removal of the freepolymer;

FIG. 5 shows the SDS-PAGE of SEC fractions obtained from fractionated PCconjugation to IFN;

FIG. 6 shows the Western Blot analysis of PEG-IFN (left side gels) andPC-IFN (right side gels) after incubation for 1 week at 4° C., ambient(20° C.) and 37° C.;

FIG. 7 shows the Western Blot analysis of PC-IFN samples afterincubation for 1 week at 4° C. (A), 20° C. (B) and 37° C. (C);

FIG. 8 is an SEC chromatogram showing separation of 20 kDa PEGequivalent MPCylated IFN sample (Con9(2));

FIG. 9 is an SEC chromatogram showing separation of 30 kDa PEGequivalent MPCylated IFN sample (Con9(3));

FIG. 10 is an SEC chromatogram showing separation of 12 kDa PEGequivalent MPCylated IFN sample (Con9(1));

FIG. 11 is an SDS PAGE gel for MPC and PEG interferon conjugates;

FIG. 12 displays representative graphs showing the antiviral activity of(A) IFN, (B) Con9(4), (C) Con9(2), (D) Con9(3), and (E) Con9(1);

FIG. 13 shows a Western blot with anti-IFN antibody from PAGE analysisshowing (A) Con9(4), (B) Con9(1), (C) Con9(2), and (D) Con9(3);

FIG. 14 displays representative graphs showing the antiproliferationactivity of (A) IFN, (B) Con9(4), (C) Con9(2), (D) Con9(3), and (E)Con9(1);

FIG. 15 shows representative pharmacokinetic profiles of (A) IFN-α2a(Roferon-A), (B) 20 kDa PEG equivalent MPC-IFN and (C) 40 kDa PEG-IFN(Pegasys) in mice; and

FIG. 16 shows combined pharmacokinetic profiles of (A) IFN-α2a(Roferon-A), (B) 20 kDa PEG equivalent MPC-IFN and (C) 40 kDa PEG-IFN(Pegasys) in mice.

DETAILED DESCRIPTION OF THE INVENTION

Compounds of general formula I and II act as initiators in the livingradical polymerisation process according to the first aspect of thepresent invention. The initiators are extended at the carbon to which Zis attached by a living radical polymerisation process. The opposite endof the initiator molecule must be suitable for derivatisation with abiological molecule. In this regard it is vital that the initiator hasan α-methylene leaving group, or precursor to a leaving group, or adouble bond conjugated with an electron-withdrawing group. This allows abiological molecule to react with the initiator in a Michael reaction.

When referring to groups which are radicals, it is intended that thegroup can be joined to adjacent groups in either direction. For instancewhen R³ is C(═O)R¹⁰, it may be linked either R²—C(═O)R¹⁰—C in thecompounds of general formula (I), (II), (VII), (VIII), (XI), (XII) and(XIII), or R²-R¹⁰C(═O)—C.

Preferably, in compounds of formula I and II, R⁶ is —CH₂E². If theleaving group is prone to elimination rather than to direct displacementwith a nucleophile, and the electron-withdrawing group R¹ is a suitableactivating moiety for the Michael reaction then sequentialintramolecular bis-alkylation can occur by consecutive Michael and retroMichael reactions. The leaving moiety serves to mask a latent conjugateddouble bond that is not exposed until after the first alkylation hasoccurred and bis-alkylation results from sequential Michael andretro-Michael reactions.

Initiators of general formula II may have from 1 to 5 double bonds. Anucleophile may add to the conjugated system at a suitable position onany of the double bonds. Preferably, however, m is zero in an initiatorof general formula II.

Preferably, in the initiators of general formula I and II, R⁶, R⁷ and R⁸are each independently selected from —H or —CH₃.

In the initiator of general formula I or II it is preferred that onlyone of R⁴ and R⁵ is H. Preferably, neither are hydrogen. Suitably, atleast one, and preferably both of R⁴ and R⁵ are methyl.

In a preferred embodiment, R³ is —CO—R¹⁰ in which R¹⁰ is oligoalkoxy,preferably oligoethoxy in which there are 2 to 10 ethoxy groups.Alternatively, the alkoxy group may have 1 or 3 carbon atoms. In thispreferred embodiment, R⁴ and R⁵ are preferably methyl.

Group Z is a radically transferable group and is preferably a halogen,more preferably Cl, Br or I, most preferably Br. Since groups R⁴ and R⁵may also be Z the initiator may be di-, oligo- or poly-functional.

Suitable linking groups, L, include a bond, a C₁₋₁₀ alkylene group, oran optionally substituted aryl or heteroaryl, any of which groups mayhave substituents selected from optionally substituted alkoxy,oligoalkoxy, amino (including mono- and di-alkyl amino and trialkylammonium, which alkyl groups, in turn, may have substituents selectedfrom acyl, alkoxycarbonyl, alkenoxycarbonyl, aryl and hydroxy) andhydroxyl groups.

Suitable groups for electron-withdrawing group R¹ include a keto group,an ester group, and a sulphone group.

Groups E¹ and E² are typically leaving groups selected from —SR¹⁷,—SO₂R¹⁷, —OSO₂R¹⁷, —N⁺R¹⁷ ₃, —N⁺HR₂ ¹⁷, —N⁺H₂R¹⁷, halogen, or —OAr, inwhich R¹⁷ represents an alkyl or aryl group and Ar represents asubstituted aryl group containing at least one electron-withdrawingsubstituent.

Alternatively, groups E¹ and E² may be precursors to leaving groups,wherein the leaving group may be obtained by a simple chemical reactionsuch as oxidation or reduction. Having E¹ and E² as precursors toleaving groups may be preferable if this facilitates synthesis of theinitiator and the subsequent polymerisation reaction.

In a preferred embodiment of this invention, E¹ and E² are each,independently, an (optionally substituted) aryl sulfide or aryl sulfonegroup.

An aryl sulfide (a precursor to a leaving group) may be converted intoan aryl sulfone (a leaving group) by a simple oxidation reaction, as iswell know in the art. The process according to the first aspect of thisinvention may include a subsequent reaction step in which groups E¹ andE² (if present) which are precursors to leaving groups are convertedinto leaving groups.

A particularly preferred initiator of general formula I has formula

The living radical polymerisation process of the invention may be agroup transfer radical polymerisation, for instance in which an N-0, orother carbon-, sulphur-, and oxygen-centered radical group istransferred from an initiator compound to a monomer. Preferably,however, the process is an atom transfer radical polymerisation process.

The novel polymers according to the third aspect of this invention arepreferably made by the living radical polymerisation process of thefirst aspect of the invention. Other controlled polymerisationtechniques may be used for instance NO group transfer systems such asare described in WO-A 0018807, catalyst systems described in WO-A9958588, systems involving irradiation with visible light, or other EMradiation such as described in WO-A 99/10387, radical additionfragmentation chain transfer polymerisation (RAFT) as described inRizzardo, E. et al. ACS Symposium Series 2000, 768, 278-296, usingcompounds (initiators) of the general type Z—C═SSR or macromoleculardesign through interchange of xanthes (MADIX) as descried by Bontevin,B., J. Polym. Sci. PtA, Polym. Chem., 2000, 38(18), 3235-3243.

Atom or group transfer radical polymerisation processes are describedfurther in WO 02/28929.

Selection of a suitable ligand is, for instance, based upon thesolubility characteristics and/or the separability of the catalyst fromthe product polymer mixture. Generally it is catalyst to be soluble in aliquid reaction mixture, although under some circumstances it may bepossible to immobilise the catalyst, for instance an a porous substrate.For the preferred process, which is carried out in the liquid phase, theligand is soluble in a liquid phase. The ligand is generally a nitrogencontaining ligand. The preferred ligand may be a compound including apyridyl group and an amino moiety, such as bipyridine, or

where R is a suitable alkyl group, the substituent being variable andadaptable to confer desired solubility characteristics or may betriphenylphosphine or 1,1,4,7,10,10-hexamethyl-triethylene tetramine.

Such ligands are usefully used in combination with copper chloride andruthenium chloride transition metal compounds as part of the catalyst.

The living radical polymerisation process of the invention is preferablycarried out to achieve a degree of polymerisation in the range 5 to 500.Preferably the degree of polymerisation is in the range 10 to 100, morepreferably in the range 10 to 50. In the preferred group or atomtransfer radical polymerisation technique, the degree of polymerisationis directly related to the initial ratios of initiator to monomer.Preferably the ratio is in the range 1:(5 to 500), more preferably inthe range of 1:(10 to 100), most preferably in the range 1:(10 to 50).

The ratio of metal compound and ligand in the catalyst should beapproximately stoichiometric, based on the ratios of the components whenthe metal ion is fully complexed. The ratio should preferably be in therange 1:(0.5 to 2) more preferably in the range 1:(0.8:1.25). Preferablythe range is about 1:1.

In the process, the catalyst may be used in amounts such that a molarequivalent quantity as compared to the level of initiator is present.However, since catalyst is not consumed in the reaction, it is generallynot essential to include levels of catalyst as high as of initiator. Theratio of catalyst (based on transition metal compound) to initiator ispreferably in the range 1:(1 to 50), more preferably in the range 1:(1to 10).

Whilst the polymerisation reaction may be carried out in the gaseousphase, it is more preferably carried out in the liquid phase. Thereaction may be heterogeneous, that is comprising a solid and a liquidphase, but is more preferably homogeneous. Preferably the polymerisationis carried out in a single liquid phase. Where the monomer is liquid, itis sometimes unnecessary to include a non-polymerisable solvent. Moreoften, however, the polymerisation takes place in the presence of anon-polymerisable solvent. The solvent should be selected having regardto the nature of the zwitterionic monomer and any comonomer, forinstance for its suitability for providing a common solution containingboth monomers. The solvent may comprise a single compound or a mixtureof compounds.

The ethylenically unsaturated comonomers polymerised in the processaccording to the first aspect of this invention may be anionic, cationicor nonionic monomers. Two or more different ethylenically unsaturatedcomonomers may be polymerised.

The ethylenically unsaturated comonomers preferably have general formulaIII

in which R¹⁸ is selected from hydrogen, halogen, C₁₋₄ alkyl and groupsCOOR²² in which R²² is hydrogen and C₁₋₄ alkyl;

R¹⁹ is selected from hydrogen, halogen and C₁₋₄ alkyl;

R²⁰ is selected from hydrogen, halogen, C₁₋₄ alkyl and groups COOR²²provided that R¹⁸ and R²⁰ are not both COOR²²; and

R²¹ is a C₁₋₁₀ alkyl, a C₁₋₂₀ alkoxycarbonyl, a mono- or di-(C₁₋₂₀alkyl) amino carbonyl, a C₆₋₂₀ aryl (including alkaryl), a C₇₋₂₀aralkyl, a C₆₋₂₀ aryloxycarbonyl, a C₁₋₂₀-aralkyloxycarbonyl, a C₆₋₂₀arylamino carbonyl, a C₇₋₂₀ aralkyl-amino, a hydroxyl or a C₂₋₁₀ acyloxygroup, any of which may have one or more substituents selected fromhalogen atoms, alkoxy, oligo-alkoxy, aryloxy, acyloxy, acylamino, amine(including mono and di-alkyl amino and trialkylammonium), carboxyl,sulphonyl, phosphoryl, phosphino, (including mono- and di-alkylphosphine and tri-alkylphosphonium), zwitterionic and hydroxyl groups;

or R²¹ and R²⁰ or R²¹ and R¹⁹ may together form —CONR²³CO in which R²³is a C₁₋₂₀ alkyl group.

In a preferred embodiment, R¹⁸ and R¹⁹ are each hydrogen, R²⁰ is methyland R²¹ is a C₁₋₂₀ alkoxy carbonyl, optionally having a hydroxysubstituent.

In the polymers of general formula VII and VIII, residues M correspondto the ethylenically unsaturated monomers used in the process accordingto the first aspect of the invention. Preferably residues M are selectedfrom radicals of the general formula IX.

in which R¹⁸ is selected from hydrogen, halogen, C₁₋₄ alkyl and groupsCOOR²² in which R²² is hydrogen and C₁₋₄ alkyl;

R¹⁹ is selected from hydrogen, halogen and C₁₋₄ alkyl;

R²⁰ is selected from hydrogen, halogen, C₁₋₄ alkyl and groups COOR²²provided that R¹⁸ and R²⁰ are not both COOR²²; and

R²¹ is a C₁₋₁₀ alkyl, a C₁₋₂₀ alkoxycarbonyl, a mono- or di-(C₁₋₂₀alkyl) amino carbonyl, a C₆₋₂₀ aryl (including alkaryl), a C₇₋₂₀aralkyl, a C₆₋₂₀ aryloxycarbonyl, a C₁₋₂₀-aralkyloxycarbonyl, a C₆₋₂₀arylamino carbonyl, a C₇₋₂₀ aralkyl-amino, a hydroxyl or a C₂₋₁₀ acyloxygroup, any of which may have one or more substituents selected fromhalogen atoms, alkoxy, oligo-alkoxy, aryloxy, acyloxy, acylamino, amine(including mono and di-alkyl amino and trialkylammonium), carboxyl,sulphonyl, phosphoryl, phosphino, (including mono- and di-alkylphosphine and tri-alkylphosphonium), zwitterionic and hydroxyl groups;

or R²¹ and R²⁰ or R²¹ and R¹⁹ may together form —CONR²³CO in which R²³is a C₁₋₂₀ alkyl group.

Typically, in these polymers, f is in the range 5 to 50.

The ethylenically unsaturated monomers may polymerise to form a polymerselected from polyalkylene glycol, polyvinylpyrrolidone, polyacrylate,polyoxazoline, polyvinylalcohol, polyacrylamide, polymetharylamide, or aHPMA copolymer. Alternatively, the polymer may be susceptible toenzymatic or hydrolytic degradation, such as polyesters, polyacetals,poly(ortho esters), polycarbonates and polyamides.

The polymer may be a homopolymer that is moiety -(-M-)-_(f) in polymersof general formula VII and VIII may comprise groups M which are residuesof the same ethylenically unsaturated monomer. Alternatively, thepolymer may be a copolymer or a block copolymer, wherein groups M inmoiety -(-M-)-_(f) are residues of different ethylenically unsaturatedmonomers.

Preferably, the ethylenically unsaturated comonomers are zwitterionic.The zwitterionic nature arises from the combination of a cationic andanionic moiety. The cationic moiety may be an ammonium, phosphonium orsulphonium group, preferably an ammonium group. The anion is typically aphospho moiety, more typically a phosphate diester.

R²¹ is preferably a group of general formula IV

in which the moieties A¹ and A², which are the same or different, are—O—, —S—, —NH— or a valence bond, preferably —O—, and W⁺ is a groupcomprising an ammonium, phosphonium or sulphonium cationic group and agroup linking the anionic and cationic moieties which is preferably aC₁₋₁₂-alkanediyl group,

preferably in which W⁺ is a group of formula—W¹—N⁺R²⁶ ₃, —W¹—P⁺R²⁷ ₃, —W¹—S⁺R²⁷ ₂ or —W¹-Het⁺in which:

W¹ is alkanediyl of 1 or more, preferably 2-6 carbon atoms optionallycontaining one or more ethylenically unsaturated double or triple bonds,disubstituted-aryl (arylene), alkylene arylene, arylene alkylene, oralkylene aryl alkylene, cycloalkanediyl, alkylene cycloalkyl, cycloalkylalkylene or alkylene cycloalkyl alkylene, which group W¹ optionallycontains one or more fluorine substituents and/or one or more functionalgroups;

B is a bond, or a straight or branched chain alkanediyl, alkyleneoxaalkylene, or alkylene (oligooxalkylene) group, optionally containingone or more fluorine substituents; and

either the groups R²⁶ are the same or different and each is hydrogen oralkyl of 1 to 4 carbon atoms, preferably methyl, or aryl, such asphenyl, or two of the groups R²⁶ together with the nitrogen atom towhich they are attached form an aliphatic heterocyclic ring containingfrom 5 to 7 atoms, or the three groups R²⁶ together with the nitrogenatom to which they are attached form a fused ring structure containingfrom 5 to 7 atoms in each ring, and optionally one or more of the groupsR²⁶ is substituted by a hydrophilic functional group, and

the groups R²⁷ are the same or different and each is R²⁶ or a groupOR²⁶, where R²⁶ is as defined above; or

Het is an aromatic nitrogen-, phosphorus- or sulphur-, preferablynitrogen-, containing ring, for example pyridine.

More preferably, R²¹ is of general formula

where the groups R²⁵ are the same or different and each is hydrogen orC₁₋₄ alkyl, and m is from 1 to 4, in which preferably the groups R²⁷ arethe same preferably methyl.

Alternatively, R²¹ may be of the general formula VI.

In formulae IV-VI, B is preferably a straight chain C₂₋₆ alkanediyl.

An example of a suitable zwitterionic monomer is2-methacryloyloxyethyl-phosphorylcholine (MPC).

The living radical polymerisation process of the invention is preferablycarried out to achieve a degree of polymerisation in the range 5 to 500.Preferably the degree of polymerisation is in the range 10 to 100, morepreferably in the range 10 to 50. In the preferred group or atomtransfer radical polymerisation technique, the degree of polymerisationis directly related to the initial ratios of initiator to monomer.Preferably the ratio is in the range 1:(5 to 500), more preferably inthe range of 1:(10 to 100), most preferably in the range 1:(10 to 50).

The ratio of metal compound and ligand in the catalyst should beapproximately stoichiometric, based on the ratios of the components whenthe metal ion is fully complexed. The ratio should preferably be in therange 1:(0.5 to 2) more preferably in the range 1:(0.8:1.25). Preferablythe range is about 1:1.

In the process, the catalyst may be used in amounts such that a molarequivalent quantity as compared to the level of initiator is present.However, since catalyst is not consumed in the reaction, it is generallynot essential to include levels of catalyst as high as of initiator. Theratio of catalyst (based on transition metal compound) to initiator ispreferably in the range 1:(1 to 50), more preferably in the range 1:(1to 10).

Whilst the polymerisation reaction may be carried out in the gaseousphase, it is more preferably carried out in the liquid phase. Thereaction may be heterogeneous, that is comprising a solid and a liquidphase, but is more preferably homogeneous. Preferably the polymerisationis carried out in a single liquid phase. Where the monomer is liquid, itis sometimes unnecessary to include a non-polymerisable solvent. Moreoften, however, the polymerisation takes place in the presence of anon-polymerisable solvent. The solvent should be selected having regardto the nature of the zwitterionic monomer and any comonomer, forinstance for its suitability for providing a common solution containingboth monomers. The solvent may comprise a single compound or a mixtureof compounds.

It has been found that, especially where the zwitterionic monomer isMPC, that it is desirable to include water in the polymerisationmixture. Preferably water should be present in an amount in the range 10to 100% by weight based on the weight of ethylenically unsaturatedmonomer. Preferably the total non-polymerisable solvent comprised 1 to500% by weight based on the weight of ethylenically unsaturated monomer.It has been found that the zwitterionic monomer and water should be incontact with each other for as short a period as possible prior tocontact with the initiator and catalyst. It may be desirable thereforefor all the components of the polymerisation other than the zwitterionicmonomer to be premixed and for the zwitterionic monomer to be added tothe premix as the last additive.

It is often desired to copolymerise MPC or other zwitterionic monomerwith a comonomer which is insoluble in water. In such circumstances, asolvent or co-solvent (in conjunction with water) is included to confersolubility on both MPC and the more hydrophobic monomer. Suitableorganic solvents are ethers, esters and, most preferably, alcohols.Especially where a mixture of organic solvent and water is to used,suitable alcohols are C₁₋₄-alkanols. Methanol is found to beparticularly suitable in the polymerisation process of the invention.

The process may be carried out at raised temperature, for instance up to60 to 80° C. However it has been found that the process proceedssufficiently fast at ambient temperature.

The polymerisation process of the invention has been found to providepolymers of zwitterionic monomers having a polydispersity (of molecularweight) of less than 1.5, as judged by gel permeation chromatography.Polydispersities in the range 1.2 to 1.4 have been achieved. Conversionrates achieved in the process are over 90% often over 95% or higher. Itis preferred that the process be continued until a conversion level ofat least 50%, or usually, at least 70% is reached.

It is believed that this process is the first time that lowpolydispersity polymers have been formed of monomers of the generalformula III using an initiator of general formula I or II and suchpolymers form a further aspect of the invention.

In polymers of general formula VII and VIII, the preferred groups L,R¹-R⁶, Z and m are the same as for the initiator of general formula I orII. Similarly, the preferred groups for E¹ and E² are as for theinitiator compounds. However, for the novel compounds to be able toconjugate biological molecules, groups E¹ and E² (if present) should beleaving groups. Accordingly, a particularly preferred leaving group is:

and particularly preferred polymers are of formula:

The method according to the fourth aspect of this invention provides anovel method of derivatisation of a biological molecule(s). Thebiological molecule or molecules are represented by general formulaT¹D¹X and T²D²X wherein D¹X and D²X represent a nucleophillic group.Typically, the nucleophillic group is a thiol group, although amine andhydroxyl groups may also have utility.

An adduct of general formula XIII is formed when the polymer of generalformula X or XI has only one leaving group, or R³⁶ is not a leavinggroup in a polymer of general formula XI. Adducts of general formula XIImay form when a nucleophile attacks the polymer of general formula X orXI twice, i.e. when there are two leaving groups (E³ and E⁴), or R³⁶ isa leaving group in XI.

Moiety T^(x)-D^(x)- in formula XII may be derived from the samebiological molecule as T¹-D¹, in which case x is 1. Alternatively,moiety T^(x)-D^(x)- may be derived from a different biological molecule,in which case x is 2.

Typically, the derivatisation will be carried out by partially reducinga disulphide bond derived from two cysteine amino acids in the sameprotein. Since in this case T¹D¹ and R^(x)D^(x) are derived from thesame protein, x=1.

Suitably, the process according to the invention is carried out bypartially reducing a disulfide bond derived from two cysteine aminoacids in the protein in situ following which the reduced product reactswith the polymer of formula X or XI. Disulfides can be reduced, forexample, with dithiothreitiol, mercaptoethanol, ortriscarboxyethylphosphone using conventional methods. The process may becarried out in a solvent or solvent mixture in which all reactants aresoluble. The biological molecule containing nucleophilic groups (e.g.protein) may be allowed to react directly with the polymer of thegeneral formula X or XI in an aqueous reaction medium. This reactionmedium may also be buffered, depending on the pH requirements of thenucleophile. The optimum pH for the reaction is generally between about5.5 and about 8, for example 7.4, preferably about 6.0-6.5. Reactiontemperatures between 3-37° C. are generally suitable: proteins and otherbiological molecules may decompose or denature impairing function if theconjugation reaction is conducted at a temperature where these processesmay occur. Reactions conducted in organic media (for example THF, ethylacetate, acetone) are typically conducted at temperatures up to ambient,for example temperatures below 0° C.

A protein can contain one or a multiplicity of disulfide bridges.Reduction to give free sulfhydral moieties can be conducted to reduceone or a multiplicity of disulfide bridges in a protein. Depending onthe extent of disulfide reduction in the stoichiometry of the polymericconjugation reagent that is used, it is possible to conjugate one or amultiplicity of polymer molecules to the protein. Immobilised reducingagents may be used if it is desired to reduce less than the total numberof disulfides, as can partial reduction using different reactionconditions or the addition of denatures.

Alternatively the source of the thiol groups can be from cysteines orthiols not originally derived from a disulfide bridge. If the source ofthe thiol groups is a disulfide bridge, this may be intrachain orinterchain.

The biological molecule can be effectively conjugated with the polymersof the present invention using a stoichiometric equivalent or a slightexcess of polymer, unlike many prior art reagents. However, since thepolymers of the present invention do not undergo competitive reactionswith aqueous media used to solvate proteins, it is possible to conductconjugation reaction with an excess stoichiometry of polymer. The excesspolymer can be easily removed by ion exchange chromatography duringroutine purification of proteins.

The biological molecule is preferably a peptide, protein or lipoprotein.The protein may be, for example, a polypeptide, antibody, antibodyfragment, enzyme, cytokine, chemokine or receptor. Constrained or cyclicpolypeptides, which are usually cyclised through a disulphide bridge,and epitopes, may also be used.

The following gives some specific biological molecules which may haveutility in the present invention, depending upon the desiredapplication. Enzymes include carbohydrate-specific enzymes, proteolyticenzymes and the like. Enzymes of interest, for both industrial (organicbased reactions) and biological applications in general and therapeuticapplications in particular include the oxidoreductases, transferases,hydrolases, lyases, isomerases and ligases disclosed by U.S. Pat. No.4,179,337. Specific enzymes of interest include asparaginase, arginase,adenosine deaminase, superoxide dismutase, catalase, chymotrypsin,lipase, uricase, bilirubin oxidase, glucose oxidase, glucuronidase,galactosidase, glucocerbrosidase, and glutaminase.

The biological molecules conjugated in the present invention include forexample factor 8, insulin, ACTH, glucagen, somatostatin, somatotropins,thymosin, parathyroid hormone, pigmentary hormones, somatomedins,erythropoietin, luteinizing hormone, hypothalamic releasing factors,antidiuretic hormones, prolactin, interleukins, interferons, colonystimulating factors, hemoglobin, cytokines, antibodies,glycopolypeptides such as immunoglobulins, ovalbumin, lipase,glucocerebrosidase, lectins, tissue plasminogen activator andglycosilated interleukins, interferons and colony stimulating factorsare of interest, as are immunoglobulins such as IgG, IgE, IgM, IgA, IgDand fragments thereof. The biological molecule is preferably a peptidehormone.

Of particular interest are antibodies and antibody fragments which areused in clinical medicine for diagnostic and therapeutic purposes. Theantibody may be used alone or may be used covalently conjugated(“loaded”) with another atom or molecule such as a radioisotope or acytotoxic/antiinfective drug. Epitopes may be used for vaccination toproduce an immunogenic polymer-protein conjugate.

Preferably, the protein is interferon-α.

REFERENCE EXAMPLE 1

In this invention, such polymers, based upon phosphorylcholine (PC) arefunctionalised with an end-terminal linking group capable of insertioninto the disulfide bridges or reaction with terminal cysteine residuesof many commonly used therapeutic proteins. FIG. 1 shows the mechanismof PC polymer insertion.

This invention provides for a method of attaching novel PC polymers,useful for modification of proteins by virtue of their biocompatibleproperties, much akin to the PEG counterparts. The polymer is moreover,selectively attached at specific positions within the protein structuredictated by the position of the disulfide bridges or terminal cysteineresidues in the conformational tertiary structure of the protein.

EXAMPLE 1 Preparation of Benzoic Acid Derivative of the Bis-Sulfide (1)

The benzoic acid derivative of the bis-sulfide was prepared as describedby Liberatore, F., Eberle, M. & Lawton, R. G. Bioconjug. Chem. 1, 36-50(1990).

EXAMPLE 2 Preparation of the NHS Ester of the Bis-Sulfide (2)

Under an argon atmosphere, a stirred suspension of4-[2,2-bis[(polylsulfonyl)-methyl]acetyl]benzoic acid (2 g, 4 mmol),N-hydroxysuccinimide (0.483 g, 4.2 mmol, NHS, Aldrich) and anhydrousdichloromethane (5 ml, Aldrich) was cooled using an ice bath. Neat1,3-diisopropylcarbodiimide (657 μL, 4.2 mmol, DIPC, Aldrich) was thenadded dropwise. After 1.5 h, a further 60 μL of DIPC was added, andafter 3 h, the reaction mixture was passed through a non-absorbentcotton wool filter. The homogeneous filtrate was diluted withdichloromethane (≈30 ml), washed with water (2×15 ml) and dried withmagnesium sulfate. Filtration under gravity and removal of volatilesunder vacuum gave the desired active NHS ester as a solid product (1.89g, 79% yield).

H NMR: (CDCl₃, 400 MHz) δ 2.48 (s, 6H, CH₃), 2.94 (s, 4H, CH₂CH₂), 3.56(A2B2X, 4H, CH₂C), 4.38 (quintet, 1H, CH, J=6.3 MHz), 7.37, 7.70 (AB q,SO₂Ar, 8H, J=8.0 & 8.3 MHz resp.), 7.76, 8.14 (AB q, COAr, 4H, J=8.6MHz). ¹³C NMR: (CDCl₃, 400 MHz) δ 195.29, 168.92, 160.95, 145.63,139.11, 135.29, 130.92, 130.24, 129.59, 128.73, 128.28, 55.67, 35.89,25.70, 21.70. MALDI-TOF MS: m/z=620.3070 [M+Na]+.

EXAMPLE 3 Preparation of the Bis-Sulfide ATRP Initiator

Step 1: This step was performed to place a spacing unit into theinitiator that would enhance the compounds' solubility in methanol, thesolvent selected for the eventual polymerization (scheme 1). A 50 mlround bottom flask was charged with NHS ester bis-sulfide compound (1 g,1.88 mmol, 1 equivalent) and a magnetic stir bar. The flask was sealedwith a septum and purged with argon for approximately 1 min. Understirring at room temperature, neat 2-(2-aminoethoxy)ethanol (207 μl,2.13 mmol, 1.13 equivalents) was added dropwise by syringe. Theresulting solution was allowed to stir at RT overnight. After stirringfor 20 h, the solvent was removed under vacuum to leave a sticky residuewhich was immediately dissolved in ethyl acetate (50 ml) and thisorganic phase was washed with 3×30 ml of deionised water (the last 30 mlacidified with several drops of 0.1N HCl) and with a saturated brinesolution (30 ml). The organic phase was then dried with magnesiumsulfate, filtered under gravity and the solvent removed under vacuum ina 100 ml round bottom flask. The sticky residue afforded was furtherdried in a vacuum oven at RT overnight and used without furtherpurification. The mass was not recorded due to the difficulty inweighing the sample but the yield was assumed to 100% for the next step.

Step 2 (scheme 2): The residue contained in the 100 ml round bottomflask (3) was sealed with a septum and placed under an argon atmosphere.A magnetic stir bar was also added. Anhydrous dichloromethane (10 ml)was added by syringe and a homogenous solution was allowed to form.Under stirring, neat 2-bromoisobutyryl bromide (225 μl, 2.06 mmol, 1.1equivalents) was added by syringe. Next, 4-dimethylaminopyridine (11 mg,0.05 equivalents) in dichloromethane (1 ml) was added and the resultingsolution allowed to stir at RT overnight. The reaction solution wasdiluted with ethyl acetate (50 ml) and washed with deionised water (50ml), 0.1M sodium bicarbonate (15 ml), deionised water (15 ml) andfinally with saturated brine (20 ml). The organic phase was dried withmagnesium sulfate, filtered under gravity and volatiles removed undervacuum to leave a sticky product that was allowed to further dry in avacuum oven at RT. Analysis by ¹H NMR showed the product to becontaminated with a small amount of NHS ester starting compound fromstep 1. Therefore, final purification was achieved using dry flashchromatography. A no. 2 sintered glass funnel (4 cm diameter) was filledwith approximately 3 cm depth of silica (BDH, code 153325P). A portionof the product (0.3 g) was dissolved in a small volume ofdichloromethane and added to the silica. The column was eluted with 25ml portions of dichloromethane, ethyl acetate:hexane (1:2 v/v), ethylacetate:hexane (1:1.5 v/v) and ethyl acetate:hexane (1:1 v/v). Theelution of compounds was followed by TLC analysis (ethyl acetate:hexane1:1 v/v, UV lamp detection) of the fractions obtained. The ethylacetate:hexane (1:1.5 v/v) fractions were shown to contain the majorproduct (Rf about 0.4) and these fractions were combined and volatilesremoved under vacuum to leave the final product ((4) 0.13 g).

EXAMPLE 4 MPC Polymer Synthesis Using Bis-Sulfide Linker (4) as ATRPInitiator

A typical ATRP synthesis of MPC homopolymer from bis-sulfide initiator(4) is shown in the Scheme 3. Bis-sulfide initiator (4) (120 mg, 0.18mmol) was dissolved in 5 mL methanol. After the solution was purged withnitrogen for 40 min, catalysts Cu(I)Br (25.8 mg, 0.18 mmol) andbipyridine (56.2 mg, 0.36 mmol) were added to the reaction flask,followed by the addition of MPC monomer (3.68 g, 12.6 mmol) at 20° C.The reaction was stirred under nitrogen atmosphere overnight, and wasstopped by adding excess methanol. The MPC polymer (5) was purified bypassing through a silica gel column [silica gel 60 (63-200 mm)] toremove the catalysts, and being further precipitated in acetone solvent.The collected polymer was vacuum dried. Scheme 3 shows the synthesis ofMPC homopolymer (5) by ATRP.

EXAMPLE 5 Oxidation of the Bis-Sulfide MPC Polymer to Bis-Sulfone (6)

To ensure that efficient protein conjugation could be performed with MPCpolymers of type (5) it was necessary to oxidise the bis-sulfide endgroup to the desired bis-sulfone (Scheme 4). The thiol ether selectiveoxidation reagent Oxone (Aldrich) was used to achieve this mildoxidation.

Proton NMR analysis of the product (6) from oxidation was consistentwith the desired structure (FIG. 3 a). Signals for the aromatic groupsof the linker moved further down field (see protons labelled 1, 2, 3, 4& 5 in FIGS. 3 a & 3 b) in the ¹H NMR spectrum compared to the precursorstarting polymer (5). As expected, all starting bis-sulfide (5) wasoxidised. There was no evidence that any other functional group in theMPC polymer (5) was affected during the oxidation. The PEG equivalent Mwof (5) and the oxidised product (6) were calculated by SEC. Thecharacterisation results of various polymers are listed in Table 1.

TABLE 1 Characterisation data for various MPC polymers Polymer Mn Mn(SEC, No. (NMR) RALS detector) PD 5(1) Bis-sulfide linker-MPC 56,00044,900 1.28 6(1) Bis-sulfone linker-MPC 35,100 41,800 6(2) Bis-sulfonelinker-MPC 62,500 37,800 1.19 6(3) Bis-sulfone linker-MPC 47,800 21,2001.20 6(4) Bis-sulfone linker-MPC 41,300 25,500 1.24

EXAMPLE 6 Conjugation of MPC Bis-Sulfone to IFN

Before the conjugation of MPC bis-sulfone (6(1)) to IFN, the MPC polymer(5(1)) was further fractioned by using Superdex™ 200 protein SEC column.The fraction of elution which was equivalent to PEG 20k Da was collectedand oxidised to bis-sulfone as described in Example 5.

To 1.00 ml of Interferon-α (IFN) (0.3 mg/ml) in PBS (pH 7.85, 2 mM EDTA)was added dithiothreitol (DTT, 15.4 mg, 100 mM, excess) and aftervortexing for several seconds until homogenous the resulting solutionwas allowed to stand at room temperature for 30 mins. The solution wasthen diluted with fresh buffer (500 μl) to give 1.50 ml in total. TheDTT was removed and the buffer changed to PBS pH 8.20, 5 mM EDTA, usinga protein desalting column (HiTrap, Amersham Biosciences, 17-1408-01).The column was eluted with 1 ml followed by 0.8 ml of buffer after thesample was loaded. The two elutes, collected separately(A_(280 nm)=0.068 and 0.093 respectively), were combined and 20 μl takenfor further analysis on SDS PAGE. MPC bis-sulfone (4 mg, (6)) was addedto the 1.8 ml of reduced protein and after vortexing until homogeneousthe solution was kept at 4° C. overnight without stirring or agitation.A sample (20 μl, was taken for PAGE analysis and to the remainingsolution was added 100 μl of an oxidising glutathione solution (preparedfrom 1.5 mg reduced glutathione and 3.0 mg oxidised glutathionedissolved in 1 ml of PBS pH 8.2) and stored at 4° C. overnight.

FIG. 4 shows the SEC trace which confirmed the presence of mono-(64.35min) and di-PCylated IFN (55.67) plus some aggregate (47.40 min),together with the free IFN (99.37 min).

The SEC fractions obtained from the fractionated PC-IFN conjugate weretaken and run on an SDS-PAGE (4-12% Bis-Tris gel, MOPS buffer,non-reducing conditions, silver staining). FIG. 5 shows the PAGE tracewhich clearly shows two distinct sets of bands separated by lanes 5 and6, one set mid-way between the 64 k and 191 k markers and the other atthe 191 k marker boundary, which correspond to the mono and di-PCylatedIFN species as seen on the SEC trace in FIG. 4.

EXAMPLE 7 Western Blots of PEG-IFN and PC-IFN Conjugates

PCylated IFN and a comparative PEGylated IFN prepared using the samebis-sulphone linker as described in WO 2005/007197 were subjected toWestern blot analysis using a polyclonal antibody against IFN alpha(FIG. 6). In FIG. 6, numbers on the top relate to the time of elution ofthe sample from SEC. Native IFN-α is denoted as N. The primaryantibodies were incubated for 48 hours. Optimisation of antibodydilution and the length of incubation was required to improve thedetection of PC-IFN.

PEGylation is known to cause steric shielding and consequently affectsthe way an antibody binds to a PEGylated protein. One aim of Westernblot analysis was to assess the extent of steric shielding caused byPCylation in comparison to PEGylation. When equal loadings of PEG-IFNand PC-IFN were analysed (as determined by the height of the SEC tracepeak at specific time points), no bands were detected for PC-IFN (datanot shown).

To facilitate the detection of PC-IFN bands, larger volumes of PC-IFNwere required. The largest volume of PC-IFN (20 μl) was therefore loadedas shown in Table 2 and a longer incubation protocol was employed (48 hincubation with 1:10,000 anti-IFN primary antibody). It is to be notedthat since the PEG-IFN samples were more dilute than the PC-IFNconjugates, is was not possible to match the highest PC conjugateconcentration with the PEG samples due to the restriction in PAGE sampleloading volume.

TABLE 2 Height of SEC trace and the gel loading volume for Western blotanalysis. Time Height of SEC trace (mV) SDS-PAGE loading (μl) (min)PEG-IFN PC-IFN PEG-IFN PC-IFN 51 19.4 25 20* 20 53 55.5 61.4 20* 20 5535.5 81.8 20* 20 57 22.6 77.3 20* 20 59 100 70.5  14.1 20 61 174 77.3  8.9 20 63 74.2 97.7 20* 20 65 16.1 102.3 20* 20 *Loading limit of thegel used.

As shown in FIG. 6 (wherein left and right gels are PEG-IFN and PC-IFNrespectively, and native IFN-α is denoted as N), the resulting Westernblot gave intense bands for PC-IFN, confirming the presence of IFN. Themigration of the bands obtained correlate with the PAGE gel obtained inFIG. 5. This result strongly suggests that there may be more sterichindrance of the protein to antibody caused by PC compared to PEGpolymer.

EXAMPLE 8 Stability of Purified PCylated IFN Conjugates and Comparisonwith Peg-IFN

The PC-IFN conjugate samples obtained from the SEC run presented in FIG.4, were incubated at 4° C., ambient temperature (20° C.) and 37° C. forone week and analysed by Western blot (FIG. 7) to assess stability.

After the 7 day incubation and at all temperatures, both PC and PEGsamples showed excellent stability. All samples remained as high MWbands indicating no breakdown and release of IFN from either PC or PEGconjugates.

Unconjugated IFN-α aggregated readily under storage at 37° C. Forconjugates, there was a progressive propensity to form aggregates withincreasing storage temperature and a difference was seen between PC andPEG samples. With PEG-IFN samples at 4° C., predominantly unaggregatedbands were observed. At RT and 37° C., multiple bands of higher MW wereclearly visible across all time points, presumably relating toaggregated species. Surprisingly, this effect was less for the PCsamples, where the high MW aggregate band was only visible at 37° C.This suggests that the PCylated IFN has a lower tendency to aggregatethan PEGylated IFN.

In summary, from Examples 7 & 8 we can conclude that PC-IFN did interactas easily with the primary antibody as well as PEG-IFN, indicating thePC polymer may be causing greater steric hindrance than the PEG polymer.This could result in lower opsonisation in vivo and hence longerresidence time. If the steric effects reduced interaction with thetarget ligands, then there might also be option to administer a higherdose without toxicity.

The PC-IFN had a tendency for far less aggregation than the PEG-IFN,even at 1 week at 37° C. This could provide formulation advantages. Itmight also mean that the conjugate may not be lost as easily duringmanufacture and storage by interaction with the separating columns orthe glass storage vials.

Furthermore, we found that the PC-IFN conjugate is stable at 1 week at37° C. with no signs of loss of polymer from the conjugate. The linkeris therefore stable and thus no loss of protein from the system shouldoccur in vivo.

EXAMPLE 9 Preparation of Polymers and Conjugates for In Vitro EvaluationSize-Exclusion Chromatography (SEC) for MW Determination

The SEC system comprised a guard column and two Viscotek 7.8 mm×30 cmGMPW_(xl) columns connected to a Visocotek Model 270 series dualdetector (right-angle laser light scattering (RALLS) and viscometer) anda Viscotek VE 3580 RI detector. The three detectors together comprisedthe ‘TriSEC system’ referred to herein. The equipment was calibratedusing a PEG standard of MW 21,450 (Polymer Laboratories). The SEC eluentused was either 0.2 M NaNO₃ with 10% acetonitrile or PBS at pH 7.3 usinga flowrate of 0.7 ml/min. The TriSEC system was controlled usingViscotek OmnicSEC 3.1 software. Samples were prepared at a concentrationbetween 3 and 5 mg/ml in the eluent and filtered through 0.2 μm Anotop10 filters (Whatman, cat. no. 6809-1022). All samples were run intriplicate and the results averaged. The do/dc value used (0.142)obtained from a standard ATRP MPC polymer as described in WO02/28929 ofMn58,000, Mw 68,900 and Mw/Mn of 1.19, run at concentrations of 5, 4, 3,2 and 1 mg/ml (from a stock solution of 80 mg 792BB/13 in 4 ml buffer)and using the OmniSEC software. Conventional calibration was obtainedusing a set of PEG standards (Polymer Laboratories and Fluka) with Mpvalues of 167.7, 126.5, 82.3, 40.0, 19.2 and 12.3 kDa on the same SECsystem.

Fractionation of MPC Polymers

Aqueous solutions (150 mg/ml) of two MPC bis-sulfide polymers, bothtarget degrees of polymerisation (Dp) of 20 made as per Examples 1-4 (2ml), were separately prepared. For the first, 2×1950 μl was runseparately on the SEC system described above (Superdex 200 column)running in pH 4.0, 20 mM sodium acetate at 1 ml/min and with UVdetection at 280 nm. Fractions of elute were collected every 1 minuteduring peak elution and stored at 4° C. until required. The secondsample was run once (also 1950 μl injected) under the same conditions.

MPC bis-sulfones, 12, 20 and 30 kDa PEG equivalent MWs, ran on SEC withsodium acetate buffer, pH 4.0, resulted in peaks whose retention timesat the maximum peak height were 70.50, 61.25 and 55.38 min respectively.Therefore, all the 69-70, 70-71 and 71-72 min fractions were combined (9ml); as were the 60-61, 61-62 and 62-63 min fractions (9 ml). The 54 to56 min fractions were not considered concentrated enough to give enoughpolymer for conjugation, therefore the 57-58, 58-59 and 59-60 minfractions were combined (9 ml).

Each of the three 9 ml samples were then concentrated to about 1 mlusing a Vivaspin 6 ml centrifugal concentrator (MWCO 5 kDa, 4 k rpm)ready for oxidation of the end group to the bis-sulfone which isdescribed below.

Oxidation of Fractionated MPC Bis-Sulfide To MPC Bis-Sulfone

The three concentrated samples from the fractionation step wereseparately diluted with methanol (1 ml) and Oxone (5 mg) added to each.The resulting mixtures (2 ml) were allowed to stir at RT overnight. Theliquid phases were then isolated by centrifugation followed bydecantation. Each solution was diluted to 2.5 ml with fresh deionisedwater and then buffer exchanged/purified using PD-10 columns (Pierce)pre-equilibrated with deionised water. The purification resulted inthree 3.5 ml solutions to which was added chilled acetone (10 ml toeach). The resulting precipitates were isolated by centrifugation (4 krpm for 15 min) and allowed to dry under vacuum at RT to give threesolid products. These were coded Poly9(1) (46 mg), Poly9(2) (27 mg) andPoly9(3) (18 mg) for 12, 20 and 30 kDa MPC respectively. All samplesstored under argon at −18° C. until needed.

After oxidation of the end-group to the bis-sulfone form, two of the MPCpolymers that were fractionated with pH 4.0 acetate as the mobile phasegave peaks consistent with their fractionation conditions (20 and 30 kDaPEG equivalent MWs). For the MPC bis-sulfone obtained using from SECfractions that eluted after 70 min (12 kDa PEG equivalent MW), thechromatogram was broad. One possibility is that the broadness was aconsequence of the excellent separation of the Superdex 200 proteincolumn at this molecular weight, since the same sample run on a moretraditional SEC column (Triple detection SEC data) gave a lowpolydispersity (Mw/Mn=1.12) only slightly broader than the higher MWsamples (Mw/Mn=1.07 for both 20 kDa & 30 kDa equivalent MPC polymers).Interestingly, after conjugation with IFN, analysis of the resultingproduct by PAGE and western blot suggested that this may actually be aheterogeneous polymer (see in vitro analysis below).

Conjugation of MPC Bis-Sulfone to IFN

The best conditions currently observed for the conjugation of MPCbis-sulfone to IFN are described. IFN-alpha-2a (1 mg, Peprotech cat. no.300-02A, lot no. 081CY28) was reconstituted from a powder with deionisedwater (1 ml) and the absorbance checked at 280 nm. The solution was thenadded to dithiothreitol (DTT, 10 μl of a 0.4 M stock solution, 4 mM DTTfinal concentration) and after gentle rotation for several seconds untilhomogenous the resulting solution was allowed to stand at RT for 30mins. The DTT was then removed and the buffer changed to PBS pH 8.20, 5mM EDTA, using a PD-10 desalting column (PD-10, GE Healthcare, cat. no.52-1308-00). The column was pre-equilibrated with the PBS pH 8.20, 5 mMEDTA and the protein solution added. The column was then eluted with 5×1ml of fresh buffer added, collecting each 1 ml elution separately.Fractions 3 and 4 were identified to be containing reduced protein bytheir A280 nm readings (typically A280 nm=0.70 and 0.25 respectively)and combined to give 2 ml.

The solution was then added to a fresh 2 ml microfuge tube containingthe MPC bis-sulfone polymer (11 mg) and a solution allowed to form withgentle shaking. The solution was then placed in the fridge (4° C.)overnight. An oxidising glutathione solution (50 μl, prepared from 1.5mg reduced glutathione and 3.0 mg oxidised glutathione dissolved in 1 mlof PBS, pH 8.2) was added and the solution returned to the fridgeovernight. The solution was diluted to 2.5 ml with fresh buffer (500 μl)and then buffer exchanged to 10 mM Tris pH 8.0 (no NaCl) using a PD-10column as per the supplied instructions (GE Healthcare, 3.5 ml solutionresulting). The polymer-conjugate was then isolated by ion-exchangechromatography followed by size-exclusion chromatography as describedbelow.

Three batches of MPC-IFN were prepared with MPC polymer that was firstfractionated to have comparable solution size to 12, 20 and 30 kDa PEG.The SEC chromatograms obtained at the final stage of purification areshown in FIGS. 8-10. In these Figures, the samples are from E2+E3 IEXfractions with a pH 7.3 PMS mobile phase. FIG. 8 shows Con9(2), FIG. 9shows Con9(3) and FIG. 10 shows Con9(1). A 20 kDa PEG-IFN conjugate wasalso prepared for comparison. As previous, all batches were purified byIEX followed by SEC. The IEX fractions chosen for SEC were those deemedthe most rich in protein species as determined by their A_(280 nm)readings. Therefore, not all the conjugate possible was isolated, justan amount sufficient for further study. Consequently, the following SECchromatograms do not necessarily represent the true level of conjugationachieved since the samples had already been semi-purified by IEXchromatography.

All the MPC conjugates had relative MWs of between 65 to 191 kDa by SDSPAGE (FIG. 11). In this SDS run SeeBlue protein markers (Invitrogen)were used on a 4-12% Bis-Tris gel with MOPS buffer under reducingconditions. The 20 kDa PEG-IFN conjugate (Con9(2)) had a relative MW ofbetween 64 and 51 kDa (FIG. 11) and was therefore smaller than all theMPC conjugates by PAGE. It is well documented in the literature that PEGruns ‘larger’ than an equivalent MW protein in SDS PAGE which separatesdue to size only. For example, under these conditions, a 20 kDa PEG runsonly as far as a protein with an approximate MW of 40 kDa. Consistentwith the SEC result, the 12 kDa PEG equivalent MPC sample (Con9(1))appears to give a higher dispersity conjugate. However it was possibleto fractionate the conjugate by using some of the SEC fractionsobtained.

Anion Exchange Chromatography and Size-Exclusion Chromatography

A 1 ml HiTrap Q FF column (GE Healthcare, cat. no. 17-5053-01) wasequilibrated with 10 mM Tris buffer, pH 8.0 (No NaCl). The proteinsolution was loaded on to the column using a peristaltic pump and thefiltrate collected as the ‘load’ fraction. The column was then washedwith 5×1 ml fractions of fresh 10 mM Tris buffer collecting 5 fractions(W1 to W5) to remove unreacted MPC polymer. The column was then elutedwith 5×1 ml fractions of 10 mM Tris buffer containing 0.7 M NaCl toelute all protein species (collecting E1 to E5). Example A_(280 nm)readings: W5=0.032, E1=0.030, E2=0.748, E3=0.339, E4=0.051, E5=0.028.For all samples, fractions E2 and E3 were identified as containing thehighest concentration of protein species by their A_(280 nm) readingsand were subsequently combined and purified by SEC-HPLC in a single run(PBS pH 7.3). Fractions were collected every 1 min during the peakelution and stored immediately at 4° C. For PEG-IFN, E2 was run on SECwithout combining with E3. Which SEC fractions were used for in vitroevaluation is described in the in vitro experimental methods below. Foridentification, the experiment codes were: 12 kDa PEG equivalentMPC-IFN=Con9(1), 20 kDa PEG equivalent MPC-IFN=Con9(2), 30 kDa PEGequivalent MPC-IFN=Con9(3) and 20 kDa PEG-IFN (prepared at pH 7.8, with1 mg IFN and 1.4 mg PEG bis-sulfone)=Con9(4).

Quantification of Protein in Polymer Conjugates.

The concentration of IFN in the conjugate solutions was determined byBCA assay. The BCA assay was performed as the manufacturer'sinstructions (Micro BCA assay kit, Pierce, cat. no. 23235). Briefly, 150μl of reagent was mixed with 150 μl of sample and the absorbancemeasured at 570 nm. The concentration was determined after obtaining astandard curve from different concentrations of unconjugated IFNstandard. The protein content of all SEC fractions were in the range4-15 μg/ml. The MPC polymer on its own and in the presence ofnon-conjugated IFN and was shown not to interfere with the BCA assay.

EXAMPLE 10 Antiviral Activity of MPC-IFN Conjugates

The most important in vitro activity of IFN-alpha is its ability toprotect cells from virus-induced cytopathic cell death. In this study,we have used human A549 lung fibroblast cells and encephalomyocarditisvirus (EMCV), which are reliably and routinely used in IFN-α studies.The samples used for the antiviral in vitro study were obtained directlyfrom SEC using the conjugates described in Example 9: 12 kDaMPC-IFN=Con9(1); 20 kDa MPC-IFN=Con9(2); 30 kDa MPC-IFN=Con9(3) and 20kDa PEG-IFN=Con9(4).

A549 cells cultured in DMEM supplemented with 10% foetal calf serum(FCS) and antibiotics (penicillin/streptomycin) were trypsinised andsuspended at a concentration of 0.2×10⁶ cells/ml. Cells were then platedat 50 ml/well on a 96-well flat-bottom tissue culture (TC) plates andwere allowed to adhere at 37° C. On the following day, MPC-IFN sampleswere diluted in DMEM/10% FCS at twice the desired concentration andadded to wells (50 ml/well) in quadruplicates. After 24 h, media wasremoved and an inoculum of EMCV that causes cell death in positive wellswithin 24 h was added to each well (50 ml/well). The TC plates werecultured until virus-induced cell death was observed in 80% of wells.Media containing the virus was removed and the cells washed with PBS toremove cellular debris. Cells were then stained with 4%formaldehyde/0.1% methyl violet 2B (50 mg/well) for 30 minutes. Stainwas then removed, and the TC plate washed twice with PBS and air dried.Wells stained purple indicates the presence of A549 cells protected fromEMCV-induced cell death. Stain was solubilised in 10% SDS (50 ml/well)and the absorbance measured at 570 nm.

Antiviral activity is a well described and widely accepted procedure forthe biological evaluation following any modification of IFN. It is theprimary measure of in vitro biological activity of IFN and PEGylatedIFN. IFN conjugated with 12 kDa, 20 kDa and 30 kDa PEG equivalentmolecular weight MPC polymers were tested in this assay and theirresults compared to native IFN and PEGylated IFN.

The antiviral activity of IFN-alpha-2a (as used in this study) is alsoreported in the literature and was used as an internal standard toconfirm the validity of the antiviral assays that were performed withMPC-IFN. The ED₅₀ of IFN was evaluated to be 12±1 pg/ml (n=4).Representative antiviral assay graphs for the polymer conjugates arepresented in FIG. 12 and the averaged values presented in Table 3.

TABLE 3 Antiviral assay ED₅₀ values for MPCylated and PEGylated IFNconjugates. Values are averaged from multiple repeats (see experimentalsection). Experiments from these ED₅₀ values were selected from havebeen verified using IFN as control. PEG Equivalent ED₅₀ % of IFN Samplemolecular weight (pg/ml) activity IFN — 12 ± 1  100% PEG-IFN (Con9(4))20 kDa  75 ± 30 16.1% MPC-IFN (Con9(2)) 20 kDa  66 ± 10 18.1% MPC-IFN(Con9(3)) 30 kDa 255 ± 41  4.7% MPC-IFN (Con9(1)) 12 kDa >4,600  0.3%

Consistent with expectations for PEGylated proteins, the 20 kDa PEG-IFNhad a higher ED₅₀ value (i.e, less activity) than unconjugated IFN,which was measured to be 75±30 pg/ml (n=3) Like PEG-IFN, all theMPCylated IFN samples had antiviral activity. The 20 kDa PEG equivalentMW MPCylated IFN sample gave an ED₅₀ value (66±10 pg/ml, n=6) and iscomparable to the 20 kDa PEG-IFN. This indicates that MPC and PEG of thesame hydrodynamic volume affects the antiviral activity similarly invitro.

The 30 kDa PEG equivalent MW MPCylated IFN gave a lower ED₅₀ value thanfor the 20 kDa samples at 255±41 pg/ml (n=4). This is the general trendthat is observed in the literature and could be due to the larger sizeof the MPC polymer causing greater steric shielding compared to the 20kDa samples. Since MPC is zwitterionic there may be other features ofMPC that influence activity that are not present with PEG. There isstill significant activity with the MPC 30 kDa (PEG equivalent)conjugate. Both the 20 and 30 kDa PEG equivalent MPC-IFN conjugatesdisplay in vitro activity that warrants evaluation of pharmacokineticproperties.

Without any information about the pharmacokinetic properties of MPCalone, it is difficult to predict how MPC-IFN will differ from PEG-IFN.It is however quite remarkable that the 20 kDa equivalent MPC-IFNdisplays in vitro activity that is comparable to the 20 kDa PEG-IFNsample. In contrast, the 12 kDa PEG equivalent MW IFN sample displayedless activity. FIG. 13 shows a Western blot with anti-IFN antibody fromPAGE analysis. The 12 kDa Con9(2) and 30 kDa Con9(3) are each PEGequivalent MWs. The PEG sample had 1 day incubation with primaryantibody and the MPC samples 3 days. The ED₅₀ value was >4,600 pg/ml(n=4). Western blot data for the IFN conjugates (FIG. 13) reveals thatthe 12 kDa MPC sample may not be as homogeneous as the other samples andmay therefore not be a true reflection of 12 kDa MPC-IFN conjugateactivity. It is not clear what has happened to the 12 kDa sample but thewestern blot is heterogeneous (FIG. 13, lane B). It is possible that thesample has aggregated since distinct bands can be seen. The proportionof MPC to IFN may be such as to offer little protection to proteinaggregation.

As described in Example 8, PEG-IFN is much better visualised by Westernblot compared to the MPC-IFN samples at similar concentrations in thisantibody based experiment. Only a single day incubation with primaryantibody is required for PEGylated IFN as opposed to three days for MPCsamples. This indicates better shielding of the protein by MPC polymerover PEG. It is again interesting therefore that the antiviral resultswere similar for the 20 kDa MPC and PEG conjugates. Mechanisms of IFNclearance from the bloodstream include not only kidney ultrafiltration,but also digestion by proteases, diffusion into tissues andreceptor-mediated cellular uptake. Consequently, the half-life ofMPCylated IFN may possibly be extended compared to a PEGylated IFN ofthe same hydrodynamic volume while retaining equivalent antiviralactivity.

EXAMPLE 11 Antiproliferation Assay of MPC-IFN Conjugates

IFN-alpha also has an antiproliferation activity in Daudi cells invitro. Proliferative activity of Daudi cells were measured by thecolorimetric conversion from soluble MTT to insoluble MTT formazan. Thesamples used for the antiproliferation in vitro study were obtaineddirectly from SEC using the conjugates described in Example 9: 12 kDaMPC-IFN=Con9(1); 20 kDa MPC-IFN=Con9(2); 30 kDa MPC-IFN=Con9(3) and 20kDa PEG-IFN=Con9(4). Molecular weights for Con9(1), Con9(2) and Con9(3)are all PEG-equivalent MWs.

Daudi cells cultured in RPMI 1640 supplemented with 10% FCS andantibiotics were suspended in 0.2×10⁶ cells/ml and plated into around-bottom TC plate at 10,000 cells/well (50 ml/well). MPC-IFN sampleswere diluted in RPMI 1640/10% FCS at twice the desired concentration and50 ml added to wells in quadruplicates. After 72 h, 20 ml of MTT(Sigma-Aldrich cat. no. M5655-1G; 5 mg/ml in RPMI 1640) was added toeach well and incubated for 5 h at 37° C. TC plate was then centrifugedat 1,800 rpm for 10 minutes and the supernatant carefully removed. Toeach well was added 50 ml of DMSO (Sigma-Aldrich cat. no. 154938-2L),agitated at 600 rpm until MTT formazan crystals were completelydissolved and the optical density measured at 570 nm.

One of IFN's immunomodulatory functions is to decrease the proliferativeability of several types of non-immune cells. Antiproliferative activityof MPCylated and PEGylated IFN was therefore investigated using a wellestablished Daudi cell method (FIG. 14 and Table 4). Compared tounconjugated IFN the antiproliferation activity of the 20 kDa PEG-IFNwas 3.9%. The 20 kDa and 30 kDa MPCylated IFN samples both exhibitedsimilar antiproliferation activities to the 20 kDa PEG-IFN with valuesof 3.2% and 1.1% respectively. These results suggest that the factorswhich reduce the antiviral activity, such as the steric shielding causedby the presence of PEG or MPC polymer, are similarly influential to thereduction in the protein's antiproliferation activity. Also, aspreviously seen, the 30 kDa MPCylated IFN was less active than the 20kDa MPC-IFN. Again, it is not clear whether such a small differencemight be a significant factor for in vivo studies. The influence of MPCin vivo due to the zwitterionic charge, greater MPC solution density andthe overall steric shielding cannot yet be inferred. The literaturevalue for 40 kDa amine PEGylated IFN-alpha-2b is 2% when compared tounmodified IFN-alpha-2b (Ramon et al. (2005) PEGylatedInterferon-alpha2b: A Branched 40K Polyethylene Glycol Derivative,Pharmaceutical Research, 22:1374-1386).

TABLE 4 ED₅₀ values for the antiproliferation activities (Daudi cellassay) of IFN, PEG-IFN and MPC-IFN. PEG Equivalent ED₅₀ % of IFN Samplemolecular weight (pg/ml) activity IFN — 17 ± 2  100%  PEG-IFN (Con9(4))20 kDa 435 ± 116 3.9% MPC-IFN (Con9(2)) 20 kDa 524 ± 113 3.2% MPC-IFN(Con9(3)) 30 kDa 1,498 ± 330  1.1% MPC-IFN (Con9(1)) 12 kDa >4,600>0.3% 

EXAMPLE 12 Pharmacokinetic Study of MPC-IFN in Mice

Briefly, the time courses were determined according to the predictedhalf lives of known IFN species (see Table 5). For each time point, 5mice were injected subcutaneously and at a later time sacrificed andexsanguinated for serum preparation. Serum samples were frozen at −20°C. in 20 μl aliquots and stored in a −80° C. freezer until use.

TABLE 5 Sample collection time points following subcutaneous injectioninto mice. Time (h) after injection 0.5 1 2 4 6 12 24 48 72 IFN-α2a X XX X X X (Roferon-A) 40 kDa PEG-IFN X X X X X X X (Pegasys) 20 kDa eq X XX X X X X MPC-IFN

Antiviral assay was used to determine the presence of the IFN species.For each time point, one vial from each mouse was pooled. Two sets ofpooled serum samples were used for pharmacokinetic analysis. IFN-α2a(Roferon-A, Roche) and 40 kDa PEG-IFN (Pegasys, Roche) were also testedin parallel as reference. Since MPCylated and PEGylated IFN in serumcannot reliably be measured directly, a fixed amount of serum wasassayed for each time point and the change in the antiviral activitieswas used as a measure of the amount of IFN present in the serum, ie. adownward trend in antiviral activity is indicative of IFN clearance.Data analyses were performed using GraphPad Prism software. Allstatistical values shown are expressed as mean±SEM.

The representative absorption and elimination half-lives of IFN, 20 kDaPEG equivalent MPC-IFN and 40 kDa PEG-IFN (Pegasys) are shown in FIG.15, and the average values are provided in Table 6. Absorption half-life(

; t_(1/2)abs) and elimination half-life (

; t_(1/2)elim) were measured. Each time point is pooled from 5 serumsamples. Roferon-A was used as reference for IFN-α2a (FIG. 15A). IFNshowed a mean elimination half-life of 0.8 h (n=3). An accurateabsorption half-life could not be measured as no ascending trend wasseen with all of the time points despite the doses were givensubcutaneously, which suggests that IFN is able to enter the bloodstreamwithin 30 min of subcutaneous injection. The 40 kDa (2×20 kDa branched)PEG-IFN (Pegasys) was used as a second reference (FIG. 15C). In mice, 40kDa PEG-IFN showed a mean absorption half-life following a subcutaneousinjection of 7.4 h (n=3). Elimination half-life was measured as >50 h(n=3) as two out of three values exceeded the range of time course (>60h). This is consistent with the literature. The pharmacokinetic resultfor 20 kDa PEG equivalent MPC-IFN showed a substantial extension ofblood retention time over that of unconjugated IFN (FIG. 15B). Theabsorption half-life of MPC-IFN was determined to be 7.3±0.3 h (n=3).This was comparable to that of 40 kDa PEG-IFN (7.4±0.2 h). Theelimination halflife was 24±2 h (n=3). This compares favourably to bothIFN (<1 h) and the 20 kDa disulfide bond PEGylated IFN (12.3 h).

TABLE 6 Comparison of absorption and elimination half- lives of IFN(Roferon-A), 20 kDa PEG equivalent MPC-IFN and 40 kDa PEG-IFN (Pegasys).Absorption Elimination t_(1/2) t_(1/2) t_(max) IFN (n = 3) <0.5* 0.8 ±0.1  0.8 ± 0.2 20 kDa Peg eq MPC-IFN (n = 3) 7.3 ± 0.3 24 ± 2  16 ± 4 40kDa PEG-IFN (n = 3) 7.4 ± 0.2 >50** 16 ± 4 20 kDa PEG-IFN [1] 3.3  12.34 [1] Shaunak S, et al. Site-specific PEGylation of native disulfidebonds in therapeutic proteins. Nature Chem. Bio. 2, 2006, 312-313. *Nodata point before 0.5 h; **two t_(1/2) values > 60 h

Alternatively, data points from individual data sets were pooled (n=8)to obtain a combined pharmacokinetic profile for the native, MPCylatedand PEGylated IFN. Data points were expressed as a percentage of maximumactivity. FIG. 16 and Table 7 illustrates the results obtained from thecombined pharmacokinetic profiles. Absorption half-life (

; t_(1/2)abs) and elimination half-life (

; t_(1/2)elim) were measured. Each data point is pooled from 8experimental sets, expressed as percentage of its maximum activity.Native IFN (Roferon-A) showed an elimination half-life of 1 h (FIG. 16A)while 40 kDa PEG-IFN (Pegasys) had an elimination half-life of >60 h(FIG. 16C). For 20 kDa PEG equivalent MPC-IFN, the elimination half-lifewas 28.3 h. As previously shown, the absorption half-lives of 20 kDa PEGequivalent MPCIFN and 40 kDa PEG-IFN were very similar. Overall, theseresults fell within the parameters of pharmacokinetic profiles mentionedin Table 7.

TABLE 7 Combined pharmacokinetic profiles: Comparison of absorption andelimination half-lives of IFN (Roferon-A), 20 kDa PEG equivalent MPC-IFNand 40 kDa PEG-IFN (Pegasys). Absorption Elimination t_(1/2) t_(1/2)t_(max) IFN (n = 3) <0.5 1 1 20 kDa Peg eq MPC-IFN (n = 3) 7.5 28.3 1240 kDa PEG-IFN (n = 3) 7.4 >60 12 20 kDa PEG-IFN [1] 3.3 12.3 4

Taken together, these results clearly indicate that the conjugation ofMPC to IFN leads to a substantial extension in the elimination half-lifeof IFN. Surprisingly, the extension of IFN half-life observed for the 20kDa PEG equivalent MPC-IFN was greater than the half-life for 20 kDadisulfide bond PEGylated IFN, which is about 12 h. The MPCylated IFNalso retains around twice the biological activity of its PEGylatedequivalent. Furthermore, MPC polymer provides improved protein shieldingfrom antibodies PEG (as suggested from the Western blotting analysis).

What is claimed is:
 1. A compound of general formula XII or XIII

wherein Groups M are the same or different and are residues ofethylenically unsaturated monomers; f is 1 to 500; x is 1 or 2; p is1-5; R¹ is an electron-withdrawing group selected from the groupconsisting of a keto group, an ester group, and a sulphone group; R² isselected from C═O, C(═O)NR⁹ or a bond; wherein R⁹ is H or C₁₋₄ alkyl; R³is selected from the group consisting of C₁-C₂₀ alkylene, C₃-C₈cycloalkylene, C(═O)R¹⁰, C(═O)NR¹¹, C₁-C₂₀ alkoxy, C₂-C₂₀ alkenylene,C₂-C₂₀ alkenyl oxiranylene, arylene, heterocyclene and aralkylene; inwhich 0 to all of the hydrogen atoms are replaced with halogen, C₁-C₆alkyl optionally substituted with 1 to 2 substituents selected from thegroup consisting of C₁-C₄ alkoxy, aryl, heterocyclyl, C(═O)R¹³,C(═O)NR¹¹R¹², oxiranyl and glycidyl; R¹⁰ is alkylene of from 1 to 20carbon atoms, alkoxy from 1 to 20 carbon atoms, oligo(alkoxy) in whicheach alkoxy group has from 1 to 3 carbon atoms, aryloxy orheterocyclyloxy; any of which groups may have substituents selected fromoptionally substituted alkoxy, oligoalkoxy, amino (including mono- anddi-alkyl amino and trialkyl ammonium, which alkyl groups, in turn, mayhave substituents selected from acyl, alkoxycarbonyl, alkenoxycarbonyl,aryl and hydroxy) and hydroxyl groups; R¹¹ and R¹² are independently Hor alkyl of from 1 to 20 carbon atoms, or R¹¹ and R¹² may be joinedtogether to form an alkanediyl group of from 2 to 5 carbon atoms, thusforming a 3- to 6-membered ring; R⁴ and R⁵ are each independentlyselected from H, Z, halogen, C₁₋₂₀ alkyl, C₃-C₈ cycloalkyl, OH, CN,C₂-C₂₀ alkenyl, C₂-C₂₀ alkenyl oxiranyl, C(═O)R¹³, glycidyl, aryl,heterocyclyl, arylkyl, aralkenyl, in which 0 to all of the hydrogenatoms are replaced with halogen, C₁-C₆ alkyl optionally substituted with1 to 2 substituents selected from the group consisting of C₁-C₄ alkoxy,aryl, heterocyclyl, C(═O)R¹³, C(═O)NR¹¹R¹², oxiranyl and glycidyl; whereR¹³ is alkyl of from 1 to 20 carbon atoms, alkoxy of from 1 to 20 carbonatoms, oligo(alkoxy) in which each alkoxy group has 1 to 3 carbon atoms,aryloxy or heterocyclyloxy any of which groups may have substituentsselected from optionally substituted alkoxy, oligoalkoxy, amino(including mono- and di-alkyl amino and trialkyl ammonium, which alkylgroups, in turn may have substituents selected from acyl,alkoxycarbonyl, alkenoxycarbonyl, aryl and hydroxy) and hydroxyl groups;and L is a linking group; Z is selected from the group consisting of Cl,Br, I, OR¹⁴, SR¹⁵, SeR¹⁵, OP(═O)R¹⁵, OP(═O)(═OR¹⁵)₂, O—N(R¹⁵)₂ andS—C(═S)N(R¹⁵)₂, where R¹⁴ is alkyl of from 1 to 20 carbon atoms in whicheach of the hydrogen atoms may be independently replaced by halide, R¹⁵is aryl or a straight or branched C₁-C₂₀ alkyl group, and where anN(R¹⁵)₂ group is present, the two R¹⁵ groups may be joined to form a 5-or 6-membered heterocyclic ring; T is a conjugated biological molecule,the biological molecule being selected from the group consisting of apeptide, a protein and a lipoprotein; and D is S, NH or O.
 2. Apharmaceutical composition comprising a compound according to claim 1,and a pharmaceutically acceptable diluent or carrier.
 3. A compoundaccording to claim 1, wherein the biological molecule is interferon-α.4. A composition according to claim 2, wherein the biological moleculeis interferon-α.